ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SALV Salvarx Group Plc

4.50
0.00 (0.00%)
23 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.50 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

SalvaRx Group plc Transaction Update (1025I)

21/11/2018 1:00pm

UK Regulatory


Salvarx (LSE:SALV)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Salvarx Charts.

TIDMSALV

RNS Number : 1025I

SalvaRx Group plc

21 November 2018

SalvaRx Group plc

("SalvaRx", the "Company" or the "Group")

Transaction Update

Further to the announcements of 14 and 28 August 2018 relating to the proposed disposal of the Company's 94.2% interest in SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company is pleased to announce that the Portage shareholder meeting to approve the transaction has been set for 8 January 2019 and meeting materials will be sent to Portage shareholders on the Portage record date, being 23 November 2018. Trading in Portage shares on the Canadian Securities Exchange is expected to resume shortly after the meeting materials have been posted.

The Company will now finalise and publish its shareholder circular and a further announcement will be made by the Company in due course.

Enquiries

 
 SalvaRx Group plc 
 Ian Walters (Chief Executive)                  Tel: +1 203-441-5451 
 Northland Capital Partners Limited             Tel: +44 (0) 20 
  Nominated Adviser and Broker                   3861 6625 
 Matthew Johnson / Edward Hutton (Corporate 
  Finance) 
 Vadim Alexandre (Corporate Broking) 
 Peterhouse Capital Limited                   Tel: +44 (0) 20 
  Joint Broker                                 7469 0932 
  Lucy Williams / Duncan Vasey 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DISPGGGAGUPRGPG

(END) Dow Jones Newswires

November 21, 2018 08:00 ET (13:00 GMT)

1 Year Salvarx Chart

1 Year Salvarx Chart

1 Month Salvarx Chart

1 Month Salvarx Chart

Your Recent History

Delayed Upgrade Clock